Author: Vere Hodge, R Anthony
Title: Meeting report: 30th International Conference on Antiviral Research, in Atlanta, GA, USA Document date: 2018_6_28
ID: tudwns0r_81
Snippet: The vaccine efficacy was evaluated in male A129 mice. On day 0, one group were vaccinated (sc, 10 4 IFU) and two groups given placebo. On day 28, it was confirmed that all the vaccinated mice had high levels of antibodies but undetectable in the two placebo groups; that day, the vaccinated group and one of the placebo groups were challenged with ZIKV (strain from Puerto Rico, PRVABC59, 10 5 IFU). Viraemia on day 30 (two days after challenge) were.....
Document: The vaccine efficacy was evaluated in male A129 mice. On day 0, one group were vaccinated (sc, 10 4 IFU) and two groups given placebo. On day 28, it was confirmed that all the vaccinated mice had high levels of antibodies but undetectable in the two placebo groups; that day, the vaccinated group and one of the placebo groups were challenged with ZIKV (strain from Puerto Rico, PRVABC59, 10 5 IFU). Viraemia on day 30 (two days after challenge) were high in the challenged-placebo group but undetectable in the other two groups. Tissues were harvested on day 49 (21 days after virus challenge). The virus levels in the testis tissue were high in the challenged-placebo group ($ 4 log 10 IFU/g) but undetectable in the other two groups. The sperm counts were low in the challenged-placebo group ($ 10 Â 10 6 /ml) but equally high ($ 20 Â 10 6 /ml) in the other two groups. The difference was even more marked when measuring motile sperm, being undetectable in the challenged-placebo group but equal (up to 10 Â 10 6 /ml) in the other two groups. In all these tests using male mice, the differences between the challenged-placebo group and the other two groups were highly significant but the results for the vaccinated group and the double-placebo (healthy mice) group were similar, the differences being not significant.
Search related documents:
Co phrase search for related documents- antibody high level and high level: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57
- antibody high level and vaccinated mouse: 1
- antibody high level and vaccine efficacy: 1, 2, 3
- antibody high level and virus challenge: 1, 2, 3, 4, 5
- antibody high level and virus level: 1, 2, 3
- challenge day and double placebo: 1, 2, 3
- challenge day and high level: 1
- challenge day and placebo group: 1, 2, 3, 4, 5
- challenge day and vaccinated group: 1, 2, 3, 4, 5
- challenge day and vaccine efficacy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- challenge day and virus challenge: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35
- challenge day and virus level: 1, 2, 3
- challenge placebo and double placebo: 1, 2, 3, 4, 5
- challenge placebo and group challenge placebo group: 1
- challenge placebo and placebo group: 1, 2, 3, 4, 5, 6, 7
- challenge placebo and vaccinated group: 1
- challenge placebo and vaccine efficacy: 1, 2
- challenge placebo and virus challenge: 1, 2, 3, 4
- challenge placebo group and group challenge placebo group: 1
Co phrase search for related documents, hyperlinks ordered by date